PANCREATIC ADENOCARCINOMA

This study tested a sequence of drugs to control advanced pancreatic cancer that has spread. 75 patients received an initial combination of chemotherapy plus drugs that modify gene activity and boost the immune system. Those whose disease was controlled then received additional i…

This study tested a combination of three chemotherapy drugs (paclitaxel protein bound, cisplatin, and gemcitabine) in 34 people with advanced pancreatic cancer that had spread. If the cancer worsened, patients could also receive an additional drug called paricalcitol. The goal wa…

This study tested a combination of two drugs—niraparib (a targeted therapy) plus either ipilimumab or nivolumab (immunotherapies)—in 104 adults with advanced pancreatic cancer that had not worsened after initial platinum chemotherapy. The goal was to see if the combo could keep t…

This study tested several combinations of immunotherapy drugs in 341 people with pancreatic cancer that had spread to other parts of the body. Participants were split into two groups: those who had not yet received any treatment for their advanced cancer, and those who had alread…

This study tested a combination of four drugs (paclitaxel protein bound, gemcitabine, cisplatin, and paricalcitol) given before surgery to people with pancreatic cancer that could be removed or was borderline removable. The goal was to see if this treatment could shrink tumors en…

This study compared two types of surgery for removing tumors in the pancreas and nearby areas: robotic-assisted surgery and traditional open surgery. The main goal was to see which approach helps patients recover basic functions like walking, eating, and stopping pain medicine so…

This study looked at 546 people who had surgery for pancreatic cancer. It tested whether adding the drug erlotinib or radiation therapy to standard chemotherapy could help them live longer. The goal was to kill any remaining cancer cells and improve survival, but the results help…

This early-phase trial tested a new treatment called CTX131 for adults with several types of advanced solid tumors that had stopped responding to standard therapies. CTX131 uses a patient's own immune cells that are edited with CRISPR technology to target a protein called CD70 on…

This study looked at small molecules called microRNAs found in pancreatic tumor tissue samples from 57 patients. The goal was to see if certain microRNA patterns are linked to how aggressive the cancer is, how long patients live, and how they respond to treatment. Researchers col…

This study tested if it is safe and possible to collect a blood sample from the portal vein (a major vein near the liver) during a routine endoscopic ultrasound in 23 people with pancreatic cancer. The goal was to find and count circulating tumor cells (cancer cells that have bro…

This study involved 247 pancreatic cancer patients and tested a computer model that learns from CT scans and tumor tissue to predict how the disease will progress and how well chemotherapy might work. The goal was to see if artificial intelligence could help doctors make better t…

This study looked at whether it is safe and possible to grow mini-tumors (organoids) from pancreatic cancer samples in the lab. Researchers took small tissue samples from 60 patients during surgery or a biopsy. They then tried to grow organoids and test different chemotherapy dru…